Nectar Lifesciences board approves unaudited financial results

14 Nov 2019 Evaluate

Nectar Lifesciences has informed that the Board of Directors of the Company at their meeting held today duly approved and took on record the Unaudited Standalone & Consolidated Financial results for the quarter and half year ended on September 30, 2019, which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.

The above information is a part of company’s filings submitted to BSE.

Nectar Lifesciences Share Price

30.25 0.20 (0.67%)
28-Mar-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1620.50
Dr. Reddys Lab 6171.85
Cipla 1494.65
Zydus Lifesciences 1013.75
Lupin 1617.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.